{ "Ferumoxytol for Iron Deficiency Anemia in Children with Chronic Kidney Disease", "This study is looking at two medicines, ferumoxytol and iron sucrose, to treat iron deficiency anemia (low iron in the blood) in children aged 2 to 17 years who also have chronic kidney disease (CKD). Researchers want to see if ferumoxytol is safe and works as well as iron sucrose. They will also study how ferumoxytol moves through the body. To join, children need to have low hemoglobin (a protein in red blood cells) and either low transferrin saturation (TSAT) or low ferritin (proteins that store iron). The study aims to see if hemoglobin levels increase by at least 0.5 g/dL by Week 5. About 129 children are expected to participate, but the current status of the study is unclear.", "design": "This is a Phase 3, randomized, open-label study involving about 129 participants. Participants will be randomly assigned to receive either ferumoxytol or iron sucrose.", "commitments": "Total participation in the study will be up to 7 weeks, including a 2-week screening period and a 5-week treatment period. Participants will receive two intravenous (IV) infusions of ferumoxytol or multiple doses of iron sucrose, depending on their kidney disease status.", "compensation": "Not stated in the trial record.", "follow_up": "The primary endpoint for measuring success is at Week 5 (35 days) after starting treatment.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.